What is the ECOG (Eastern Cooperative Oncology Group) performance status and how is it assessed?

ECOG Performance Status: Definition and Assessment

The ECOG (Eastern Cooperative Oncology Group) Performance Status is a 0–4 scale that quantifies a patient's functional capacity, where 0 represents full activity and 4 represents complete disability; it is assessed by observing the patient's ability to perform daily activities and self-care, though it is inherently subjective and prone to inter-rater variability. 1

Scale Structure

The ECOG PS uses five discrete grades:

• Grade 0: Fully active, able to carry on all pre-disease activities without restriction 1
• Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out light work 1
• Grade 2: Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours 1
• Grade 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours 1
• Grade 4: Completely disabled; cannot carry on any self-care; totally confined to bed or chair 1

Assessment Method and Key Considerations

The assessment is made through direct observation of the patient's functional abilities, focusing on their capacity for self-care and daily activities rather than disease symptoms alone. 1

Critical Assessment Pitfalls

• Age bias: Clinicians systematically assign higher (worse) numeric PS scores to patients aged >65 compared to younger patients, despite no objective difference in measured physical activity 1
• Inter-rater variability: Agreement between assessors is only moderate (Cohen's κ = 0.486), with 71% concordance between physicians and nurses 2
• Nurse versus physician ratings: Nurse-assessed ECOG PS scores more accurately predict 1-month chemotherapy toxicity (OR 1.44), 1-month hospitalizations (OR 1.57), and 6-month mortality or hospice referrals (OR 3.29) compared to physician assessments 2
• Physician-nurse disagreement: When physicians assign "healthier" (lower) scores than nurses, outcomes are significantly worse (6-month mortality OR 2.99) 2
• Specialty differences: Palliative care specialists rate ECOG PS a median of +0.5 points higher than medical oncologists, and palliative care nurses rate +1.0 point higher 3

Underlying Etiology Matters

The cause of poor performance status is clinically critical but not captured by the ECOG scale itself. 1

• When low-functioning PS stems from disease burden (e.g., brain edema, raised intracranial pressure), targeted treatment may improve functional status with tumor control 1, 4
• Current PS scales do not differentiate between disease-related versus comorbidity-related functional impairment 1
• Predictors of discordance between specialists include presence of potentially effective treatment (OR 2.39) and poor feeling of well-being (OR 2.38) 3

Relationship to Karnofsky Performance Status

ECOG PS correlates strongly with the Karnofsky Performance Status (KPS) scale (Spearman R = -0.869), with ECOG demonstrating superior prognostic discrimination. 5

Conversion Between Scales

The most accurate three-point conversion achieves 84% agreement: 5

• Grade 1: KPS 100,90,80 ≈ ECOG 0–1
• Grade 2: KPS 70,60 ≈ ECOG 2
• Grade 3: KPS <60 ≈ ECOG 3–4

ECOG PS should be preferred over KPS because it shows better ability to discriminate patients with different prognoses in both univariate and multivariate survival analyses. 5

Clinical Implications and Prognostic Value

ECOG PS is one of the most powerful prognostic factors in oncology, correlating with overall survival, progression-free survival, and treatment-related complications. 1

Performance Status 2 Patients

• PS 2 patients constitute a significant proportion of the cancer population but are frequently excluded from clinical trials 6
• In meta-analysis of 36 pivotal trials, PS 2 participants showed no statistically significant difference in progression-free survival (HR 0.45 vs 0.52, p=0.59) or overall survival (HR 0.81 vs 0.71, p=0.18) compared to PS ≤1 patients 6
• However, higher proportion of PS 2 participants was significantly associated with increased risk of serious adverse events, AE-related deaths, and treatment discontinuations 6
• Expanding trial eligibility to include PS 2 patients may result in faster accrual rates and more representative trial populations without substantially diluting treatment effects. 1

Performance Status 3–4 Patients

• Patients with ECOG 3–4 (equivalent to KPS ≤60) are generally not candidates for active systemic therapy due to poor tolerance and limited expected benefit 4
• The primary therapeutic goal for these patients should be symptom management and quality-of-life preservation, not disease-directed treatment 4

Limitations of ECOG PS

ECOG PS is a unidimensional, subjective functional score that fails to account for multimorbidity, frailty, or cognition. 7

• It is open to investigator bias and lacks objective measurement 1, 7
• PS is less predictive of cancer-related outcomes in older adults 1
• The scale does not capture changes in patient status over time when assessed only once 7
• Patients with recent changes in functional status have difficulty selecting an appropriate response 8
• Most patients use assistive devices and modifications but do not incorporate these into their ECOG rating 8

Emerging Approaches

Patient-reported ECOG PS is feasible, with patients generally understanding the scale as intended, though questions remain about optimal recall period and whether to include assistive devices in instructions. 8

Moving beyond ECOG PS to incorporate additional assessment tools—particularly the Clinical Frailty Score—can better identify deficits that may be reversed and help design appropriate treatments and rehabilitation interventions. 7